Agomab News Today

-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming

-- Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors -- -- Funding will support next stage of clinical and corporate development

Agomab Therapeutics NV ('Agomab') today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference

Agomab Therapeutics NV ('Agomab') today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.

-- Acquisition strengthens Agomab as a leader in targeting growth factor pathways -- -- Origo brings TGF-ß-targeted approach with clinical-stage program in Crohn's disease and preclinical candidate

AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators -- Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan -- AgomAb Therapeutics N.V. announced today the closing of a $74 million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingel...